-
2023-05-24
Altamira Therapeutics Reports Positive Top-Line Data from Bentrio Clinical Trial in Seasonal Allergic Rhinitis
Bentrio® meets primary efficacy endpoint in NASAR clinical trial in seasonal allergic rhinitis
-
2023-04-25
优锐医药First-in-Class慢阻肺管线中国III期顺利启动，加速推进呼吸特药精耕
动脉网获悉，专注呼吸类创新药的生物医药公司：优锐医药，已经于2023年4月6日完成Ensifentrine ENHANCE - CHINAIII期临床试验的首例患者给药，适用于中国大陆区域慢性阻塞性肺疾病(COPD)疾病的维持治疗。
-
2023-04-24
优锐医药受邀出席中关村肾病血液净化创新联盟 “峥嵘五年 再续华章” 五周年庆典
优锐医药荣获联盟颁发的【企业公益大使形象TOP10】奖项
-
2023-04-17
优锐医药恩塞芬汀中国III期临床试验 全国研究者会顺利召开
2023年4月7日，由优锐医药主办的用于治疗慢性阻塞性肺疾病（COPD）新药恩塞芬汀 中国III期临床试验 ENHANCE - CHINA （RPL554 - CPC001）全国研究者会在中国广州隆重召开
-
2023-04-10
Nuance Pharma Announces Dosing of First Patient in ENHANCE – China Phase 3 Trial for COPD
Verona Pharma plc (Nasdaq: VRNA) announces its development partner, Nuance Pharma, has dosed the first subject in its ENHANCE - China Phase 3 trial for the maintenance treatment of COPD
-
2023-04-06
Ensifentrine Completes Dosing of First Patient in ENHANCE - CHINA Phase III Trial for COPD
Nuance Pharma announces dosing of first patient in the ENHANCE - China Phase III Trial for the maintenance treatment of chronic obstructive pulmonary disease ("COPD") of its novel
-
2023-03-14
Bentrio™鼻喷剂 活力上线 亮相中国香港！
优锐医药亚太区域首款商业产品，Bentrio™鼻喷剂已在中国香港首发上市！
-
2023-03-03
Clinical Study Demonstrates Bentrio's Superior Nasal Residence Time and Rheological Properties
Altamira Therapeutics Ltd. reported that data from a recent peer-reviewed clinical study involving Bentrio nasal spray's residence time and other rheological properties demonstrated superiority vs. a saline control.
Contact PR
